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Introduction: Edoxaban is an oral, once-daily direct factor Xa (FXa) inhibitor. Although rapidly cleared, strategies
to reverse edoxaban-mediated effects on anticoagulation are needed in cases of excessive bleeding or emergency.
This study evaluated the effect of two prohemostatic agents, recombinant factor VIIa (rFVIIa) and factor VIII
inhibitor bypass activity (FEIBA), on the anticoagulatory effects of supratherapeutic concentrations of edoxaban
in human whole blood ex vivo.
Materials and Methods: Blood samples were collected from six healthy volunteers. Edoxaban (500 or
1000 ng/mL), alone or followed by rFVIIa (0.8 or 1.8 μg/mL) or FEIBA (0.75 or 1.5 U/mL), was added to an aliquot
of each sample. Biomarkers, including prothrombin time (PT), activated partial thromboplastin time (aPTT),
extrinsic FXa activity (anti-FXa), intrinsic factor X activity, and D-dimer, were assessed at 0.25, 0.5, 1, 2, and
4 hours after adding rFVIIa or FEIBA.
Results: Decreases in measures of PT (p b 0.0001), aPTT (p b 0.0001), and anti-FXa (p b 0.0001) were observed
when rFVIIa or FEIBA was added to edoxaban-containing blood samples. Intrinsic FX activity was increased up
to 20% and 31% of normal in the presence of edoxaban by rFVIIa and FEIBA, respectively. The impact of these
agents on the anticoagulant effects of edoxaban were observed within 15 minutes and remained relatively
unchanged at each timepoint thereafter.
Conclusions: The ﬁndings of this ex vivo study suggest that rFVIIa and FEIBA rapidly reversed edoxaban-mediated
anticoagulation effects based on PT and aPTT, but had minimal effect based on intrinsic FX activity. No dose
response was observed for rFVIIa or FEIBA.
© 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).Introduction
Edoxaban is a novel, oral, once-daily direct inhibitor of both free and
bound activated factor X (FXa) [1], which has been evaluated for stroke
prevention in patients with non-valvular atrial ﬁbrillation [2] and for
the treatment and secondary prevention of recurrent thromboembolism
in patients with acute symptomatic venous thromboembolism [3].time; Cmax, Maximum plasma
ty; FEU, Fibrinogen equivalent
cular-weight heparin; NOACs,
entrates; pNA, Paranitroaniline;
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. This is an open access article underAlthough edoxaban is rapidly cleared with minimal accumulation of
plasma concentrations aftermultiple doses [4,5], strategies for reversing
its anticoagulant effects are needed to manage emergent serious
bleeding or in situations requiring immediate surgery or any inva-
sive procedure.
Currently, there are no reversal agents that have been approved to
reverse the anticoagulant effects of the novel oral anticoagulants
(NOACs)—direct FXa or direct factor IIa (thrombin) inhibitors. In addi-
tion, there are no evidence-based guidelines regarding the reversal of
these anticoagulants. As such, the management of patients receiving
NOACs who require surgery or experience emergent bleeding has
been the focus of recent publications [6–10], including consensus state-
ments from various working groups [11–13]. Prothrombin complex
concentrates (PCC) and the recombinant active form of factor VII
(rFVIIa) are hemostatic agents that could reverse the effects of direct
factor inhibitors. When complexed with tissue factor, rFVIIa activates
factor X (FX) [14,15]. Activated PCC, also known as factor VIII inhibitor
bypass activity (FEIBA), contains mainly activated factor VII and small
amounts of mainly non-activated factor II, factor IX, and FX, in addition
to the antithrombotic proteins C and S found in PCC [16–18]. FEIBA isthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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each component varies between batches. However, FEIBA has ap-
proximately equal units of factor VIII inhibitor bypassing activity
and prothrombin complex factors and 1 to 6 units of factor VIII coag-
ulant antigen per mL [16].
The potential of rFVIIa and FEIBA to reverse the anticoagulant activ-
ity of edoxaban was initially assessed in human plasma in vitro and in
an in vivo rat model for bleeding [19]. Both rFVIIa and FEIBA shortened
prothrombin time (PT) prolonged by therapeutic doses of edoxaban
(ﬁnal plasma concentrations of 150 and 300 ng/mL) in a concentration-
dependent manner. Additionally, rFVIIa and FEIBA signiﬁcantly and
dose-dependently reversed edoxaban-mediated prolongation of
bleeding time in rats infused with a high dose of edoxaban (1 mg/kg/h).
The objective of this studywas to assess the reversal of the anticoag-
ulant effects of supratherapeutic concentrations of edoxaban by various
concentrations of rFVIIa and FEIBA in humanwhole blood ex vivo. Coag-
ulation biomarkers were used to monitor the impact of these reversal
agents on the anticoagulant effects of edoxaban.Materials and Methods
Dose Selection
A stock solution of edoxaban from a single lot was made in dimethyl
sulfoxide. Aliquots of the stock solution were stored at –70 °C. Prior to
use, a fresh working solution of edoxaban was made in normal saline
solution. Supratherapeutic concentrations of 500 and 1000 ng/mL of
edoxaban were chosen based on the known therapeutic plasma level
of approximately 250 ng/mL for the maximum plasma concentration
(Cmax) of a 60-mg dose [4]. rFVIIa (NovoSeven®; Novo Nordisk, Copen-
hagen, Denmark) was added to plasma samples to produce ﬁnal con-
centrations of 0.8 and 1.8 μg/mL. This corresponds to known maximal
observed human plasma concentrations at the therapeutic doses of 40
and 90 μg/kg [14,15]. FEIBA (Baxter AG, Vienna, Austria) was added to
plasma samples to produce concentrations of 0.75 and 1.5 U/mL,–
-
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6 healthy volunteers
300 mL citrated whole blood
per volunteer
15 aliquots
Aliquots 4 15:  
20 mL incubated with 
edoxaban + FEIBA/rFVIIa for 
0.25, 0.5, 1, 2 or 4 hour(s)
Centrifuged for PPP
Measure PT, aPTT, an-FXa, intrinsic FX acvity, and  
D dimer
Aliquots 1 3:  
4 mL incubated with 
desired dose of edoxaban 
for 1 hour
Centrifuged for PPP
Fig. 1. Ex vivo study design. aPTT, activated partial thromboplastin time; FEIBA, factor VIII
inhibitor bypass activity; FXa, activated factor X; FX, factor X; PPP, platelet-poor plasma;
PT, prothrombin time; rFVIIa, recombinant factor VIIa.which corresponds approximately to human plasma concentrations at
the therapeutic doses of 50 to 100 U/kg [16].
Study Design
Collection of blood and assays were conducted by Medpace Refer-
ence Laboratories (Cincinnati, OH, USA). Blood samples were collected
in 3.2% sodium-citrate tubes from six healthy volunteers; a total volume
of 300 mL of citrated whole blood was obtained from each volunteer
(Fig. 1). For each individual donor, collected blood was pooled and
then subdivided into 15 aliquots; 4 mL each for aliquots 1–3 and
20 mL each for aliquots 4–15. Aliquots 1–3 from each donor were incu-
bated for 1 hour at 37 °C after edoxaban was added to achieve desired
concentrations of 0, 500, or 1000 ng/mL. After the 1-hour incubation,
these samples were centrifuged at 1500 g for 15 minutes at 4 °C to
yield platelet-poor plasma, whichwas then frozen at−70 °C until anal-
ysis. After edoxaban was incubated at a ﬁnal concentration of 500 or
1000 ng/mL with the blood for 1 hour, rFVIIa or FEIBA were added to
aliquots 4–15 to achieve desired concentrations, and these aliquots
were then incubated at 37 °C. After 0.25, 0.5, 1, 2, and 4 hours of incuba-
tion, 4 mL of whole blood were removed from each aliquot and centri-
fuged. The platelet-poor plasma was then frozen at−70 °C. Aliquot 1
received neither edoxaban nor reversal agent and was considered the
baseline.
Biomarker Assays
All sampleswere analyzed in one batch on each of the following bio-
marker assays on Siemens BCS analyzer (Siemens Healthcare Diagnos-
tics, Tarrytown, NY, USA) after thawing the samples at 37 °C.
PT and Activated Partial Thromboplastin Time (aPTT)
PT and aPTT were assayed through standard clotting methods using
Dade Innovin thromboplastin (Siemens Healthcare Diagnostics, New-
ark, DE, USA) and Dade Actin FSL Activated PTT Reagent (Siemens
Healthcare Diagnostics, Newark, DE, USA), respectively, according
to themanufacturer’s speciﬁcations. These assays are global coagula-
tion screening procedures: PT evaluates the extrinsic pathway of the
coagulation cascade, while aPTT evaluates the intrinsic component.
The reference ranges for PT and aPTT were 9.2 to 11.6 seconds and
23.3 to 32.1 seconds, respectively.
Anti-FXa Assay
The Biophen Heparin 6 assay (Hyphen BioMed, Neuville-sur-Oise,
France) is a kinetics method used to quantify heparin by its ability to
inhibit a constant amount of FXa in the presence of endogenous anti-
thrombin. The heparin-antithrombin complex binds to FXa. Any residual
(unbound) FXa hydrolyses an FXa-speciﬁc chromogenic substrate (SXa-
11), which results in the release of paranitroaniline (pNA), the color of
which can be measured at 405 nm. The amount of pNA released is rela-
tive to the residual FXa activity. There is an inverse relationship between
the concentration of heparin (or any direct FXa inhibitor) and the extent
of color development measured at 405 nm. The standards used in the
Biophen heparin assay are validated against international standards for
unfractionated heparin and low-molecular-weight heparin (LMWH)
and, at this time, no anti-FXa assay has been developed to express activ-
ity in ng/mL of edoxaban; thus, units of measurement are expressed as
IU/mL LMWH. The assaywas conducted according to themanufacturer’s
speciﬁcations.
Intrinsic FX Activity
The Biophen Factor X activity assay (Hyphen BioMed, Neuville-
sur-Oise, France) is a chromogenic method that measures FX follow-
ing activation with Russell’s viper venom (RVV), an enzyme extracted
from snake venom. FXa then cleaves the speciﬁc substrate SXa-11,
releasing pNA, which is measured at 405 nm. The degree of color
Fig. 3. Reversal of edoxaban-mediated aPTT prolongation by rFVIIa or FEIBA after
15 minutes of incubation. Error bars represent the standard deviation of the mean.
aPTT, activated partial thromboplastin time; FEIBA, factor VIII bypass activity; rFVIIa,
recombinant factor VIIa. *p b 0.0001 vs baseline; #p b 0.0001 vs edoxaban alone.
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are directly related, and a sample content of intrinsic FX activity is
calculated as a percent of normal plasma. The assay was conducted
according to the manufacturer’s speciﬁcations with a reference
range of 77% to 160%.
D-dimer
The Innovance D-Dimer assay (Siemens Healthcare Diagnostics,
Newark, DE, USA) is a particle-enhanced, immunoturbidimetric assay
that employs a highly sensitive and speciﬁc monoclonal antibody for
the quantitation of D-dimer in human plasma. The D-dimer cross-
linkage region has a stereo-symmetrical structure, ie, the epitope for
themonoclonal antibody occurs twice. Consequently, one antibody suf-
ﬁces to trigger an aggregation reaction, which is then detected turbidi-
metrically. D-dimer concentration in a sample is calculated from a
calibration curve and expressed as mg/L ﬁbrinogen equivalent units
(FEU). The reference range was 0.17 to 2.59 mg/L FEU.
Results of the biomarker assays were summarized using descriptive
statistics and paired t tests.
Results
PT
Edoxaban alone (500 and 1000 ng/mL) resulted in a signiﬁcant
(p b 0.0001) increase in PT with a mean (standard deviation [SD]) of
31 (3.7) seconds and 51 (9.4) seconds, respectively (Fig. 2). When
FEIBA 0.75 U/mL was added to the blood samples pre-incubated with
edoxaban 500 or 1000 ng/mL, mean (SD) PT values after 15 minutes
of incubation were 13.0 (0.8) and 16.1 (1.1) seconds, respectively,
while the addition of FEIBA 1.5 U/mL resulted in mean (SD) values of
12.6 (1.0) and 15.3 (1.3) seconds, respectively. Both doses of rFVIIa
(0.8 and 1.8 μg/mL) also induced a signiﬁcant (p b 0.0001) decrease in
PT when added to blood samples pre-incubated with edoxaban
500 ng/mL (10.6 [0.77] and 10.3 [0.49] seconds, respectively) or
1000 ng/mL (12.6 [0.69] and 13.0 [0.89] seconds, respectively).
Both FEIBA and rFVIIa reduced PT prolongation of edoxaban at the
concentrations tested by N60% and brought PT close to baseline, but
no concentration-dependent response for either FEIBA or rFVIIa was ob-
served. Prolonged incubation of anticoagulated blood with either FEIBA
or rFVIIa beyond 15 minutes did not produce any signiﬁcant effect
on PT (data not shown). When FEIBA 0.75 or 1.5 U/mL was added
to samples without edoxaban, PT was 9.8 (0.3) and 9.7 (0.3) seconds,
respectively. Either dose of rFVIIa resulted in PT values of 9.5 (0.8)
seconds when added to samples without edoxaban.Fig. 2.Reversal of edoxaban-mediated PT prolongation by rFVIIa or FEIBA after 15 minutes
of incubation. Error bars represent the standard deviation of the mean. FEIBA, factor
VIII inhibitor bypass activity; PT, prothrombin time; rFVIIa, recombinant factor VIIa.
*p b 0.0001 vs baseline; #p b 0.0001 vs edoxaban only.aPTT
Edoxaban alone (500 and 1000 ng/mL) resulted in a signiﬁcant
(p b 0.0001) increase in aPTT with a mean (SD) of 77 (6.1) seconds
and 103 (9.3) seconds, respectively (Fig. 3). When added to the blood
samples pre-incubated with edoxaban 500 and 1000 ng/mL, either
dose of FEIBA decreased theprolonged aPTT and brought it close to base-
line (b38 and b47 seconds, respectively). A concentration-dependent
decrease in aPTT values of approximately 3 seconds was observed
with the high versus low concentration of FEIBA. Similar decreases
were observed for rFVIIa and both reversed N56% of the prolonged
aPTT produced by edoxaban at any of the concentrations tested.
Prolonged incubation of anticoagulated blood with either FEIBA or
rFVIIa beyond 15 minutes did not produce any signiﬁcant effect on
aPTT (data not shown). When added to samples without edoxaban,
FEIBA 0.75 and 1.5 U/mL led to aPTT values of 26.7 (1.26) and 25.9
(1.62) seconds, respectively, while the addition of rFVIIa 0.8 or
1.8 μg/mL resulted in aPTT values of 26.3 (1.30) and 25.0 (1.38) seconds,
respectively.Fig. 4. Reversal of edoxaban-mediated effects on anti-FXa by rFVIIa or FEIBA after
15 minutes of incubation. Error bars represent the standard deviation of the mean.
FEIBA, factor VIII inhibitor bypass activity; FXa, activated factor X; LMWH, low-
molecular-weight heparin; rFVIIa, recombinant factor VIIa. *p b 0.0001 vs baseline;
#p b 0.0001 vs edoxaban alone.
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Consistent with its anticoagulation effects, edoxaban alone (500 and
1000 ng/mL) resulted in increased anti-FXa, with a mean (SD) of 25.0
(1.92) and 51.2 (7.34) IU/mL LMWH, respectively (Fig. 4). FEIBA or
rFVIIa alone (without edoxaban) had no effect on anti-FXa. In combina-
tion with either concentration of edoxaban, both doses of FEIBA and
rFVIIa resulted in an approximately 81% reduction of anti-FXa from
the observed edoxaban-mediated levels. The extent of reductions
in edoxaban-mediated anti-FXa by either dose of FEIBA or rFVIIa
was similar. Mean anti-FXa values were similar regardless of the du-
ration of incubation of anticoagulated blood with the reversal agents
(data not shown).Intrinsic FX Activity
Edoxaban alone (500 and 1000 ng/mL) resulted in about 93% inhibi-
tion of intrinsic FX activity (Fig. 5). When added to the blood without
edoxaban, FEIBA alone at concentrations of 0.75 and 1.5 U/mL increased
intrinsic FX activity to 134.0% and 155.6%, respectively, while the in-
crease in intrinsic FX activity by either dose of rFVIIa alone was approx-
imately 108% (data not shown). After 15 minutes of incubation with
the blood anticoagulated with edoxaban, FEIBA 0.75 and 1.5 U/mL re-
covered intrinsic FX activity to 24.7% and 31.4% of normal level, re-
spectively, when added to samples containing edoxaban 500 ng/mL,
and to 10.1% and 12.8%, respectively, in samples with edoxaban
1000 ng/mL. Both concentrations of rFVIIa recovered mean intrinsic
FX activity to approximately 19% and approximately 7% when added
to samples with edoxaban 500 ng/mL and 1000 ng/mL, respectively.
Mean intrinsic FX activity valueswere similar regardless of the duration
of incubation of anticoagulated bloodwith the reversal agents (data not
shown). Overall, both FEIBA and rFVIIa were able to slightly recover but
did not reverse the effect of edoxaban on intrinsic FX activity back to
baseline.D-dimer
The D-dimer levels across all of the agents in this ex vivo studywere
normal and did not change by edoxaban or the reversal agents (approx-
imately 0.6 mg/L FEU or less). However, the D-dimer level in one donor
increased from approximately 0.2 mg/L at baseline to 1.60 mg/L FEUFig. 5. Reversal of edoxaban-mediated effects on intrinsic FX activity by rFVIIa or FEIBA
after 15 minutes of incubation. Error bars represent the standard deviation of the mean.
FEIBA, factor VIII inhibitor bypass activity; FX, factor X; rFVIIa, recombinant factor VIIa.
*p b 0.0001 vs baseline; #p b 0.0001, $p b 0.0002, Δ p b 0.0005, +p b 0.002, or &p b 0.05.when the corresponding blood sample was incubated with rFVIIa
1.8 ug/mL (data not shown). The reason for this increase is not clear.Discussion
Direct factor Xa or IIa inhibitors offer an attractive alternative to
warfarin for oral anticoagulation as they do not require routine moni-
toring due to their predictable dose-dependent responses and wide
therapeutic windows and are generally associated with less bleeding,
particularly intracranial hemorrhage [20]. However, while themanage-
ment of warfarin bleeding is well established [21], methods are needed
to rapidly and completely reverse the anticoagulant effects of these new
agents in cases of serious bleeding or emergency surgery. No currently
available reversal or hemostatic agent has been approved to reverse
the effects of the new oral anticoagulants.
In this ex vivo study, we evaluated the ability of rFVIIa and FEIBA to
reverse the anticoagulatory effects of edoxaban. At the supratherapeutic
concentrations of edoxaban, both hemostatic agents provided signiﬁ-
cant, but partial, reversal of edoxaban-mediated changes to PT, aPTT,
and anti-FXa. Both rFVIIa and FEIBA had minimal effects on reversing
the edoxaban effects measured by intrinsic FX activity. Intrinsic FX
activity relies on the activation of FX (by RVV) present in the sample,
possibly a competing reaction with FEIBA. These reversal effects
reﬂected in the PT, aPTT, and anti-FXa assays were observed 15 mi-
nutes after adding either reversal agent with no change in the
three markers over the course of 4 hours, suggesting that the maxi-
mum effects of these agents are achieved rapidly.
The observed reduction in the edoxaban-mediated prolongation of
PT by rFVIIa and FEIBA in our study is similar to results obtained in pre-
clinical studies of edoxaban in rats [19]. In the rat model, both rFVIIa
and FEIBA signiﬁcantly reduced edoxaban-mediated prolongation
of bleeding time, suggesting that rFVIIa and FEIBA rapidly reverse
edoxaban-mediated anticoagulatory effects in vivo [22].
Although this study showed similar reversal by both FEIBA and rVIIa
of edoxaban-mediated effects, FEIBA should theoretically have greater
reversal effect since it contains FVIIa along with other inactivated coag-
ulation factors. In a study assessing the reversal of rivaroxaban-mediat-
ed effects on thrombin generation, FEIBA showed greater reversal
effects than rVIIa which, may reﬂect the difference in sensitivity of var-
ious coagulation assays [21]. In addition, nodose responsewas observed
for either FEIBA or rVIIa.
Failure to achieve complete reversal in this study may be due to the
supratherapeutic doses of edoxaban and the ex vivo nature of this
study. Edoxaban 500 ng/mL prolonged PT by approximately 300%
and aPTT by approximately 275%. This concentration corresponds
to a single oral dose of edoxaban 150 mg in healthy subjects (Cmax
of 487 ng/mL), which prolonged PT by 162% and aPTT by 71% [4].
This dose is 2.5 times greater than the highest edoxaban dose
(60 mg) evaluated in phase 3 trials [2,3]. Additional caveats to this
ex vivo characterization of reversal by FEIBA and rFVIIa are the lack
of pharmacokinetic effects of edoxaban, FEIBA, and rFVIIa. For exam-
ple, the Cmax of edoxaban decreases rapidly following a two-
compartment oral pharmacokinetic model. Therefore, the high levels
of anticoagulant reversal at peak concentrations would only be need-
ed for a 1- to 3-hour window post dose.
In addition, while this study demonstrates the signiﬁcant reversal of
edoxaban-mediated effects on coagulation markers, these results
should not be translated for clinical use. The correction of coagulation
biomarkers PT or aPTT does not necessarily translate to reduced bleed-
ing. In rabbit models, both PCC and rFVIIa reversed rivaroxaban- or
apixaban-mediated changes in coagulation markers without reversing
rivaroxaban- or apixaban-mediated increases in bleeding [23,24]. In
contrast, the use of a 4-factor PCC effectively reversed both edoxaban-
induced hemorrhaging and the prolongation of PT in a dose-
dependent manner in a rabbit bleeding model [25].
913A.-B. Halim et al. / Thrombosis Research 134 (2014) 909–913The use of reversal agents in a clinical setting can increase the risk for
thrombosis. Caution should be used during the administration of these
reversal agents. Currently, neither rFVIIa nor FEIBA are approved for
use as reversal agents for any direct FXa inhibitors, but rather are indi-
cated for use during bleeding episodes or surgery in patients with
inherited bleeding disorders [14,16]. Therefore, the appropriate concen-
trations of FEIBA or rFVIIa to be used in situations of emergent bleeding
or surgery for patients receiving NOACs is not known and overdosing
can lead to thrombosis.
Conclusions
Based on PT, aPTT, and anti-FXa activity, low therapeutic concentra-
tions of rFVIIa and FEIBA showed signiﬁcant and rapid reversal of the
anticoagulant effects of supratherapeutic concentrations of edoxaban.
However, minimal reversal was observed for intrinsic FX activity. In
addition, no dose response was observed for rFVIIA or FEIBA. Further
clinical studies are needed to determine the efﬁcacy and safety of rFVIIa
and FEIBA for the reversal of edoxaban-mediated anticoagulant effects
in clinical practice and the optimal dosage required across different
patient populations.
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